For biosimilar product
Ranbaxy Laboratories and EPIRUS Switzerland GmBH have announced the signing of licensing agreement for BOW015, a biosimilar version of Infliximab.Powered by Capital Market - Live News
Top Section
Explore Business Standard
Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
For biosimilar product
Ranbaxy Laboratories and EPIRUS Switzerland GmBH have announced the signing of licensing agreement for BOW015, a biosimilar version of Infliximab.Powered by Capital Market - Live News
First Published: Jan 09 2014 | 10:58 AM IST